Objective: To identify linear determinants of human aquaporin 4 (hAQP4) in the context of HLA-DRB1*03:01.
Results: Peptide hAQP4 281-300 generated a significantly (PϽ.01) greater T H 1 and T H 17 immune response than any of the other linear peptides screened. This 20mer peptide contains 2 dominant immunogenic 15mer peptides. hAQP4 [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] induced predominantly an IL-17 and granulocyte-macrophage colony-stimulating factor T H cell phenotype, whereas hAQP4 285-299 resulted in a higher frequency of T H 1 cells. hAQP4 281-300 did not interfere with recombinant AQP4 autoantibody binding.
Conclusions: hAQP4 281-330 is the dominant linear immunogenic determinant of hAQP4 in the context of HLA-DRB1*03:01. Within hAQP4 281-330 are 2 dominant immunogenic determinants that induce differential T H phenotypes. hAQP4 determinants identified in this study can serve as diagnostic biomarkers in patients with neuromyelitis optica and may facilitate the monitoring of treatment responses to pharmacotherapies.
Arch Neurol. 2012; 69(9) :1125-1131. Published online July 2, 2012 July 2, . doi:10.1001 July 2, /archneurol.2012 July 2, .1300 N EUROMYELITIS OPTICA (NMO) is a demyelinating inflammatory disorder of the central nervous system (CNS) that is clinically and pathologically defined as the co-occurrence of optic neuritis and myelitis. 1 NMO-IgG, an autoantibody that binds to human aquaporin 4 (hAQP4), is detectable in the serum of most patients with NMO. 2, 3 AQP4 plays an important role in the transportation of water across the cell membrane of multiple cell types. Within the CNS, it is highly expressed in the foot processes of astrocytes. 4, 5 There are 2 isoforms of hAQP4: M1 and the shorter M23 isoform, which lacks the first 22 amino acids but is otherwise identical in sequence. 6 Possibly because of the identification of the NMO-IgG antibody in patients with NMO, neurologists have focused on pharmacotherapies that predominantly target the humoral immune system. [7] [8] [9] There is evidence to suggest a cellular immune response in NMO. Recently, HLA
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haplotype analyses of patients with NMO suggest a positive association with HLA-DRB1*03:01 (HLA-DR17), 10, 11 a gene that codes for a major histocompatibility class (MHC) II molecule that presents linear antigens 12 to 15 amino acids in length to CD4 ϩ T cells. 12 In some patient cohorts, NMO-IgG is undetectable in a substantial number of patients with NMO. 2 In patients with NMOIgG, antibody isotype switching from IgM to IgG could not occur without CD4
ϩ T H cell involvement. 13, 14 The response to B cell-depleting therapies is not consistently beneficial in patients with NMO, [7] [8] [9] and CD3 ϩ T cells are abundantly present in NMO lesions. 15 We hypothesize that hAQP4-specific CD4 ϩ T cells play an important role in the pathogenesis of NMO.
To test our hypothesis, we screened 32 peptides of 20 amino acid length that overlap by 10 amino acids and span the entirety of hAQP4 in HLA-DRB1*03:01 transgenic mice. This process led us to identify the immunodominant linear determinants that stimulate cellular immune response in the context of HLA-DRB1*03:01. After identification of 1 immunodominant 20mer peptide, we determined dominant immunogenic 15mer peptides within. Proliferating CD4
ϩ T H cells were further defined by their expression of interferon ␥ (IFN-␥), interleukin (IL) 17, and granulocytemacrophage colony-stimulating factor (GM-CSF). (Table 2) were generated by JPT Innovative Peptide Solutions.
METHODS

PEPTIDES AND PROTEIN
MICE
Generation of transgenic mice expressing HLA-DRB1*03:01 was previously described. 16 Briefly, DRBI*0301 (DR3) transgenic mice were generated by coinjection of an HLADRoL genomic fragment and a DRB1*030113 gene fragment into (C57BL/6 ϫ DBA/2) F1 C57BL/6 embryos and backcrossed to B10 mice. 15 Subsequently, the DR3 gene was introduced into the class IInegative H2b −/− strain 16 by mating the B10.M-DRBI*0301 line with the B10.MHCII −/− line. All mice were bred and maintained in a pathogen-free mouse colony at The University of Texas Southwestern Medical Center at Dallas according to the 
ENZYME-LINKED IMMUNOSORBENT SPOT ASSAY
The frequency of IFN-␥, IL-17-, GM-CSF-, and IL-5-secreting CD4 ϩ T cells was determined by the enzyme-linked immunosorbent spot (ELISpot) assay. Groups of 3 male HLA-DRB1*03:01 mice were inoculated in the inguinal and axillary regions with 100 µg of whole-protein hAQP4 emulsified in complete Freund adjuvant in a 1:1 ratio. On day 10, lymph nodes and spleens were collected to generate single-cell suspensions. Next, cells (2.5-5.0 ϫ 10 5 cells per well) were incubated with a single overlapping hAQP4 peptide (50 µg/mL), whole-length hAQP4 (50 µg/mL), media only, or concanavalin A (1 µg/mL) for 48 hours in 96-well ELISpot plates (MultiScreen 96-Well Plates; Millipore). Capture and detection of cytokines were accomplished by using monoclonal antibodies (eBiosciences) spe- 
GENERATION OF NMO RECOMBINANT ANTIBODY AND QUANTITATIVE IMMUNOFLUORESCENCE MICROSCOPY
Recombinant monoclonal anti-hAQP4 antibody (NMO-rAb) and isotype control were generated from clonally expanded plasmablasts recovered from the cerebrospinal fluid of a seropositive patient with NMO as described previously.
17 U87MG cells stably transfected with M23 hAQP4 were grown on coverslips and fixed with 4% paraformaldehyde for 15 minutes and then rinsed with 1ϫ phosphate-buffered saline. Coverslips were subsequently blocked with 10% normal goat serum and then incubated with recombinant antibody 18 (10 µg/mL) with or without T-cell peptide (5 µg/mL; 40-fold molar excess) in 5% normal goat serum overnight at 4°C. Coverslips were washed 5 times with 1ϫ phosphate-buffered saline and then incubated with rabbit polyclonal anti-AQP4 (sc-20812; Santa Cruz Biotechnology) (4 µg/mL) in 2% goat serum and 0.1% Triton X100 for 1 hour at room temperature. Coverslips were subsequently washed and then incubated with goat antihuman AlexaFluor 488 (A-11013; Invitrogen) and goat antirabbit AlexaFluor 594 (DI-1594; Vector) in 2% goat serum for 1.5 hours at room temperature in the dark. Samples were then washed, fixed, and mounted with mounting media containing DAPI (H-1500; Vector).
Images were obtained using a spinning disc confocal microscope (Olympus Ix81; Olympus), and the amount of red and green fluorescence was quantified using Image J software (National Institutes of Health). The ratio of green to red fluorescence was measured in multiple independent fields, and the binding percentage was subsequently calculated by comparing the green to red fluorescence ratio in the presence and absence of AQP4 peptide.
STATISTICAL ANALYSIS
A 1-way analysis of variance test was used to compare the 32 different treatment groups. If the analysis of variance was found to be significant, the Bonferroni test, a pairwise post hoc test, was performed to determine which pairs of treatments were significantly different. After reviewing the graphic results for these data, only 1 peptide in this group of 32, peptide 29 (hAQP4 281-300 ), was compared with all antigen recalls. SPSS statistical software, version 19 (SPSS Inc), was used in these statistical analyses; all statistical tests were 2-sided, and P Ͻ .05 indicated significance. Figure 1 and Figure 2A and B) . T H 17 cellular immune responses by splenocytes against hAQP4 281-300 were not significantly different from those against full-length hAQP4 (Figure 1 and Figure 2B) . None of the overlapping hAQP4 or full-length hAQP4 peptides induced an IL-5-driven T H 2 response (data not shown).
THE DOMINANT IMMUNOGENIC REGIONS WITHIN hAQP4 281-300
Because of their biophysical properties, linear peptides that are bound in the antigen-binding groove of the MHC class II molecule to be presented to CD4 ϩ T cells are ideally 12 to 15 amino acids in length. 12 Thus, the immunodominant determinants within hAQP4 281-300 were identified by performing IFN-␥, IL-17, and GM-CSF ELISpot assays with 15mer peptides spanning hAQP4 281-300 (Table 2) .
In lymph node cells and splenocytes from HLA-DRB1*03:01 mice immunized with AQP4 281-300 , AQP4 284-298 induced a significantly higher T H 17 response than other 15mers (Figure 1 and Figure 3A) . AQP4 284-298 also induced the strongest GM-CSF-driven T H response in splenocytes significant from other 15mers (data not shown). Because of the insufficient number of lymph node cells, GM-CSF ELISpot assays could not be performed. AQP4 285-298 resulted in a significantly higher T H 1 response than other 15mers in lymph nodes cells (Figure 1 and Figure 3B ). There was also a trend toward higher IFN-␥ secretion in splenocytes after recall with AQP4 285-298 .
BINDING OF NMO-rAb TO SURFACE FULL-LENGTH hAQP4
We subsequently examined whether hAQP4 281-300 could inhibit the binding of NMO-rAb to surface AQP4 (Figure 4) . 17 Using a quantitative immunofluorescencebinding assay, we observed no significant inhibition of the binding of 2 NMO-rAbs in the presence of a 40-fold molar excess of hAQP4 281-300 . (Table 1) , media only, full-length hAQP4 (50 µg/mL), or concanavalin A (ConA) (1 µg/mL). Spot-forming units represent the absolute number of cells that are secreting a specific cytokine in response to antigen in the well (*P Ͻ .001). Error bars indicate SE.
COMMENT
The identification of immunodominant determinants of hAQP4 may have important implications for understanding the origin of NMO and monitoring disease activity in patients with this disorder. As previously stated, there is accumulating evidence to suggest a cellular immune response against hAQP4 in NMO. Other investigators recently identified dominant determinants of hAQP4 in different wild-type mouse strains, including C57BL/6 (H-2b) and SJL/J (H-2s) . 19, 20 One group of investigators found a dominant determinant that overlaps with hAQP4 281-300 , namely, hAQP4 [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] , in C57BL/6 mice. 20 However, it is difficult to compare this observation with ours for 2 reasons: (1) hAQP4 was obtained from different sources and (2) the C57BL/6 genetic background does not express H-2-IEα, the equivalent gene of the human class II MHC molecule HLA-DR␣.
This study specifically aimed to identify immunodominant linear determinants of hAQP4 in the context of HLA-DRB1*03:01 because this HLA haplotype was recently associated with NMO in several patient cohorts. 10, 11 ELISpot assays allowed us to determine the frequency of antigen-specific T cells specific for hAQP4 peptide determinants and to characterize their cytokine profiles. This is relevant because encephalitogenicity of T cells in another autoimmune disorder of the CNS, multiple sclerosis, 21 is largely defined by cytokine phenotype.
T H 1 cells, defined by the signature cytokine IFN-␥, were initially implicated in CNS autoimmunity. 22 Perhaps the most convincing evidence to support a pathogenic role of IFN-␥ in patients with multiple sclerosis was generated in a clinical study in which 7 of 18 patients who received recombinant IFN-␥ therapy experienced a disease exacerbation. 23, 24 In the last decade, another subclass of pathogenic CD4
ϩ T H cells was characterized by the production of IL-17. T H 17 cells appear to facilitate the initiation and perpetuation of CNS autoimmune diseases 25 and mediate proinflammatory and allergic responses. IL-17 mediates the localization of neutrophils to the sites of infection. 26 T H 17 cells have also been shown to play a critical role in the production of GM-CSF in the periphery and CNS. 27, 28 Our group and other investigators recently found that GM-CSF may play a critical role in different models of active and passive experimental autoimmune encephalomyelitis. [28] [29] [30] [31] Our own results indicated that GM-CSF is secreted by lymph node cells and splenocytes after antigen restimulation in the presence of IL-12. In an adoptive transfer model of experimental autoimmune encephalomyelitis, we also found that GM-CSF is highly expressed by encephalitogenic T cells.
The identification of AQP4 [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] infers that the cellular immune response may play a critical role in NMO disease development and progression because of its ability to stimulate a pronounced T H 17 immune response in the context of HLA-DRB1*03:01. The level of IL-17 is increased in patients with NMO during disease relapses. 32, 33 This finding would explain the presence of neutrophils at sites of tissue damage. 15 It is now recognized that T H 17 cells possess substantial plasticity compared with other T H cells. 34 In the setting of NMO, however, the increased levels of IL-6 found in the cerebrospinal fluid of patients with NMO may allow for the survival of hAQP4-specific T H 17 cells while inhibiting FOXp3 ϩ T-regulatory cells. [35] [36] [37] In addition, in a Chinese patient cohort, a polymorphism in the IL-17 gene was recently associated with anti-AQP4 antibody-positive NMO. 33 Uzawa et al 35 did not find elevated GM-CSF levels in the cerebrospinal fluid of patients with NMO and active clinical disease. However, the accumulation of eosinophils and granulocytes in the NMO lesion may suggest that this cytokine also plays a pathogenic role. 15 An animal model of NMO with the hAQP4 determinants identified in this study is currently under development in our laboratory. Perhaps more important, our observations may have immediate human applications. We are developing assays to determine a poten- (Table 2) , human AQP4 281-300 (50 µg/mL), media only, or concanavalin A (ConA) (1 µg/mL). Spot-forming units represent the absolute number of cells that are secreting a specific cytokine in response to antigen in the well (*P Ͻ .05 and †P Ͻ .01). Error bars indicate SE.
tially low frequency of hAQP4 284-298 -and hAQP4 285-299 -specific CD4 ϩ T cells in patients with NMO and controls together with other investigators. The biological relevance of linear hAQP4 determinants identified in this study in NMO disease activity and in response of patients with NMO to pharmacotherapies will ultimately have to be evaluated in controlled clinical trials. ARCH NEUROL / VOL 69 (NO. 9), SEP 2012
